Healthcare - Biotechnology - NASDAQ - IL
$ 1.73
-1.14 %
$ 63.7 M
Market Cap
-6.65
P/E
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses.[ Read More ]
The intrinsic value of one ENTX stock under the base case scenario is HIDDEN Compared to the current market price of 1.73 USD, Entera Bio Ltd. is HIDDEN
2. FUNDAMENTAL
ANALYSIS
Price Chart ENTX
FINANCIALS
0
REVENUE
-8.89 M
OPERATING INCOME
-8.89 M
NET INCOME
-7.31 M
OPERATING CASH FLOW
-17 K
INVESTING CASH FLOW
6.04 M
FINANCING CASH FLOW
42 K
REVENUE
3.02 M
OPERATING INCOME
-2.67 M
NET INCOME
5.19 M
OPERATING CASH FLOW
12 K
INVESTING CASH FLOW
1.26 M
FINANCING CASH FLOW
Balance Sheet Decomposition
Entera Bio Ltd.
| Current Assets | 11.3 M |
| Cash & Short-Term Investments | 11 M |
| Receivables | 0 |
| Other Current Assets | 238 K |
| Non-Current Assets | 508 K |
| Long-Term Investments | 0 |
| PP&E | 488 K |
| Other Non-Current Assets | 20 K |
| Current Liabilities | 1.09 M |
| Accounts Payable | 83 K |
| Short-Term Debt | 268 K |
| Other Current Liabilities | 740 K |
| Non-Current Liabilities | 288 K |
| Long-Term Debt | 512 K |
| Other Non-Current Liabilities | -224 K |
EFFICIENCY
Earnings Waterfall
Entera Bio Ltd.
| Revenue | 0 |
| Cost Of Revenue | 56 K |
| Gross Profit | -56 K |
| Operating Expenses | 8.86 M |
| Operating Income | -8.89 M |
| Other Expenses | -2 K |
| Net Income | -8.89 M |
RATIOS
0.00%
GROSS MARGIN
0.00%
OPERATING MARGIN
0.00%
NET MARGIN
-85.59%
ROE
-75.55%
ROA
-82.78%
ROIC
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Entera Bio Ltd.
| Net Income | -8.89 M |
| Depreciation & Amortization | 56 K |
| Capital Expenditures | -17 K |
| Stock-Based Compensation | 1.69 M |
| Change in Working Capital | -195 K |
| Others | -507 K |
| Free Cash Flow | -7.33 M |
Wall Street Analysts Price Targets
Entera Bio Ltd.
ENTX has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00%
DIVIDEND YIELD
0 USD
DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership
Entera Bio Ltd.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
97.2 K USD 3
9-12 MONTHS
| Date | Value | Insider | Amount | Avg Price |
|---|---|---|---|---|
|
10 months ago
Jan 12, 2024
|
Bought 9.4 K USD
|
Taitel Haya
Director |
+ 9500
|
0.99 USD |
|
10 months ago
Jan 10, 2024
|
Bought 5.86 K USD
|
Taitel Haya
Director |
+ 7615
|
0.77 USD |
|
10 months ago
Dec 22, 2023
|
Bought 17 K USD
|
LIEBERMAN GERALD M
Director |
+ 23952
|
0.71 USD |
|
10 months ago
Dec 22, 2023
|
Bought 24 K USD
|
LIEBERMAN GERALD M
Director |
+ 23952
|
1 USD |
|
10 months ago
Dec 22, 2023
|
Bought 17 K USD
|
Toledano Miranda Jayne
Chief Executive Officer |
+ 23952
|
0.71 USD |
|
10 months ago
Dec 22, 2023
|
Bought 24 K USD
|
Toledano Miranda Jayne
Chief Executive Officer |
+ 23952
|
1 USD |
|
1 year ago
Aug 22, 2023
|
Bought 11.2 K USD
|
Taitel Haya
Director |
+ 18000
|
0.6231 USD |
|
1 year ago
Aug 21, 2023
|
Bought 11.8 K USD
|
LIEBERMAN GERALD M
Director |
+ 20000
|
0.5892 USD |
|
1 year ago
Aug 21, 2023
|
Bought 24 K USD
|
Ellis Sean
Director |
+ 40000
|
0.6 USD |
|
1 year ago
Apr 04, 2023
|
Bought 30.3 K USD
|
Toledano Miranda Jayne
Chief Executive Officer |
+ 30000
|
1.01 USD |
|
2 years ago
Nov 14, 2022
|
Bought 14.2 K USD
|
Yaacov-Garbeli Dana
Chief Financial Officer |
+ 26580
|
0.536 USD |
|
2 years ago
Nov 11, 2022
|
Bought 15.6 K USD
|
Yaacov-Garbeli Dana
Chief Financial Officer |
+ 30000
|
0.52 USD |
|
2 years ago
Nov 14, 2022
|
Bought 19.4 K USD
|
LIEBERMAN GERALD M
Director |
+ 34000
|
0.57 USD |
|
2 years ago
Nov 14, 2022
|
Bought 2.36 K USD
|
LIEBERMAN GERALD M
Director |
+ 4000
|
0.59 USD |
|
2 years ago
Nov 11, 2022
|
Bought 15.9 K USD
|
Ellis Sean
Director |
+ 30000
|
0.53 USD |
|
2 years ago
Nov 11, 2022
|
Bought 26.6 K USD
|
Toledano Miranda Jayne
Chief Executive Officer |
+ 50000
|
0.5317 USD |
|
2 years ago
Jul 21, 2022
|
Bought 24.4 K USD
|
Ellis Sean
director: |
+ 14900
|
1.638 USD |
|
2 years ago
Jul 21, 2022
|
Bought 32.8 K USD
|
LIEBERMAN GERALD M
director: |
+ 19491
|
1.683 USD |
|
2 years ago
Jan 13, 2022
|
Bought 27.4 K USD
|
OSTROV GERALD M
Director |
+ 10000
|
2.7378 USD |
|
2 years ago
Jan 19, 2022
|
Bought 24.4 K USD
|
Ratan Ramesh
U.S.based CFO |
+ 10000
|
2.4364 USD |
|
2 years ago
Jan 18, 2022
|
Bought 28.5 K USD
|
JAMAS SPIROS
Chief Executive Officer |
+ 10000
|
2.85 USD |
|
2 years ago
Jan 20, 2022
|
Bought 25.2 K USD
|
Schwartz Phillip
President of R&D |
+ 10000
|
2.525 USD |
|
2 years ago
Jan 18, 2022
|
Bought 1.96 K USD
|
LIEBERMAN GERALD M
Director |
+ 700
|
2.8003 USD |
|
2 years ago
Jan 18, 2022
|
Bought 1.96 K USD
|
LIEBERMAN GERALD M
Director |
+ 700
|
2.8061 USD |
|
2 years ago
Jan 18, 2022
|
Bought 1.95 K USD
|
LIEBERMAN GERALD M
Director |
+ 700
|
2.7848 USD |
|
2 years ago
Jan 18, 2022
|
Bought 1.97 K USD
|
LIEBERMAN GERALD M
Director |
+ 700
|
2.8083 USD |
|
2 years ago
Jan 18, 2022
|
Bought 19.6 K USD
|
Mayron Ron
Director |
+ 7000
|
2.8 USD |
|
2 years ago
Jan 14, 2022
|
Bought 19 K USD
|
Toledano Miranda Jayne
Director |
+ 6800
|
2.7899 USD |
|
2 years ago
Jan 18, 2022
|
Bought 28 K USD
|
Ellis Sean
Director |
+ 10000
|
2.805 USD |
|
2 years ago
Jan 13, 2022
|
Bought 19.8 K USD
|
Malca Yonatan
Director |
+ 7232
|
2.74 USD |
7. News
Entera Bio Ltd. (ENTX) Reports Q3 Loss, Tops Revenue Estimates
Entera Bio Ltd. (ENTX) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.05.
zacks.com
- 1 week ago
Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates
JERUSALEM, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of oral peptides and small therapeutic proteins, today reported financial results and key business updates for the quarter ended September 30, 2024.
globenewswire.com
- 1 week ago
ENTX & OPK Stock May Gain Following Positive PK/PD Research Data
Entera and OPKO Health announce positive PK/PD results from their ongoing collaborative research focused on developing the first oral dual agonist GLP-1/glucagon peptide.
zacks.com
- 1 month ago
Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders
JERUSALEM and MIAMI, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (Entera), a leader in the development of orally delivered peptides, and OPKO Health, Inc. (NASDAQ: OPK) (OPKO) announced today topline pharmacokinetic/pharmacodynamic (PK/PD) results from their ongoing collaborative research combining a proprietary long-acting oxyntomodulin (OXM) analog developed by OPKO and Entera's proprietary N-Tab™ technology. The program is focused on developing the first oral dual agonist GLP-1/glucagon peptide as a potential once-daily treatment for patients with obesity, metabolic and fibrotic disorders. OXM is a naturally occurring peptide hormone found in the small intestine that acts to suppress appetite and induce weight loss.
globenewswire.com
- 1 month ago
Is Entera Bio (ENTX) Stock Outpacing Its Medical Peers This Year?
Here is how Entera Bio Ltd. (ENTX) and argenex SE (ARGX) have performed compared to their sector so far this year.
zacks.com
- 1 month ago
Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year?
Here is how Entera Bio Ltd. (ENTX) and Akebia Therapeutics (AKBA) have performed compared to their sector so far this year.
zacks.com
- 2 months ago
Entera Bio to Participate in Upcoming Investor and Scientific Conferences
JERUSALEM, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and small therapeutic proteins, today announced that management will be participating in the following investor and scientific conferences:
globenewswire.com
- 2 months ago
All You Need to Know About Entera Bio (ENTX) Rating Upgrade to Buy
Entera Bio (ENTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
zacks.com
- 3 months ago
Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates
JERUSALEM , Aug. 09, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and small therapeutic proteins, today reported financial results and key business updates for the quarter ended June 30, 2024.
globenewswire.com
- 3 months ago
3 Meme Stocks to Buy and Hold for Potential 300% Returns in 3 Years
Since 2021, meme stocks have been massive wealth creators for high-risk investors. During this period, dozens of meme stocks have delivered 5x to 10x returns within a few quarters.
investorplace.com
- 3 months ago
3 Meme Stocks That Can Surge by 200% Before 2025
The S&P 500 index is trading near record highs, and the overall outlook for the market is likely to remain bullish. While GDP growth has decelerated, the markets seem to be discounting multiple rate cuts in the next 12 to 18 months.
investorplace.com
- 4 months ago
3 Clinical-Stage Biotech Stocks to Buy for Multibagger Returns
One of the ways to make millions from the market is to identify and invest in early-stage companies. If the business takes off, multi-fold returns are in the offering.
investorplace.com
- 4 months ago
8. Profile Summary
Entera Bio Ltd. ENTX
COUNTRY
IL
INDUSTRY
Biotechnology
MARKET CAP
$ 63.7 M
Dividend Yield
0.00%
Description
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
Contact
Kiryat Hadassah Minrav Building, Jerusalem, 9112002
https://www.enterabio.com
IPO Date
June 28, 2018
Employees
17
Officers
Dr. Gregory Burshtein Ph.D.
Chief of Research & Development
Ms. Dana Yaacov-Garbeli CPA
Chief Financial Officer
Dr. Hillel Galitzer M.B.A., Ph.D.
Chief Operating Officer
Ms. Miranda J. Toledano M.B.A.
Chief Executive Officer & Director